Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Impact of t(11;14) as a sole and concomitant abnormality on outcomes in multiple myeloma.  British Journal of Haematology.  195:e113-e116. 2021
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation.  American Journal of Hematology.  96:E396-E398. 2021
2021 Autologous stem cell transplantation in the age of ANDROMEDA.  British Journal of Haematology.  193:865-866. 2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.  Bone Marrow Transplantation.  56:1364-1372. 2021
2021 Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.  Lancet Haematology.  8:e386-e387. 2021
2021 Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.  JAMA Oncology.  7:635-636. 2021
2021 New regimens and directions in the management of newly diagnosed multiple myeloma.  American Journal of Hematology.  96:367-378. 2021
2021 International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.  Leukemia.  35:18-30. 2021
2020 Age is just a number, the wrong number.  Cancer.  126:5014-5016. 2020
2020 Solid Organ Transplantation 2020
2020 Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma.  Biology of Blood and Marrow Transplantation.  26:1394-1401. 2020
2020 Assessment of measurable residual disease (MRD) in multiple myeloma: a review of the data 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma 2020
2020 Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma: further observations 2020
2020 Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients with High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis.  JAMA Oncology.  6:1759-1765. 2020
2020 Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.  Biology of Blood and Marrow Transplantation.  2020
2019 Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.  British Journal of Haematology.  186:807-819. 2019
2019 Lessons learned from checkpoint blockade targeting PD-1 in multiple myeloma.  Cancer Immunology Research.  7:1224-1229. 2019
2016 The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.  Journal of Surgical Oncology.  114:323-328. 2016
2015 Myocardial perfusion imaging determination using an appropriate use smartphone application.  Journal of Nuclear Cardiology.  22:66-71. 2015
2014 Potential of F-18 PET/CT in the Detection of Leptomeningeal Metastasis.  Rivista di Neuroradiologia.  27:685-689. 2014
2011 Long-term outcome of lobar ablation versus completion thyroidectomy in differentiated thyroid cancer.  Nuclear Medicine Communications.  32:52-58. 2011

Principal Investigator On

Investigator On

Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Bharati Vidyapeeth University 2012

    • Full Name

  • Susan Bal